ADXN Earnings Prediction
The chart below shows how ADXN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ADXN sees a +4.15% change in stock price 10 days leading up to the earnings, and a -9.92% change 10 days following the report. On the earnings day itself, the stock moves by +1.09%. This data can give you a slight idea of what to expect for the next quarter's release.
ADXN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
68.14K
-81.71%
-46.55%
Gross Margin
--
--
--
Operating Margin
-1054.24%
98.04%
35.14%
Net Margin
--
--
--
EPS
-0.02
-50.00%
-114.29%
No Data Available
ADXN Earnings Analysis
Addex Therapeutics Ltd American Depositary Shares Corporation (ADXN.O) Earnings Conference Call
Positive
GABAB Modulator Program Success: Excellent progress in our GABAB positive allosteric modulator program with the completion of the R&D phase delivering multiple drug candidates.
Milestone Payment Eligibility: Addex is eligible for payment of up to $330 million on successful achievement of specified regulatory, clinical, and commercial milestones.
GABAB PAM Program Advancement: We have selected a compound to advance our own independent GABAB PAM program for the treatment of chronic cough.
Clinical Candidate Efficacy Results: Our clinical candidate has demonstrated a consistent minimum effective dose of 1 mg per kg and ED50 of 6 mg per kg in cold frequency.
IND Enabling Studies Timeline: We are on track to start IND enabling studies early H1 2025.
Negative
Net Loss Comparison: The company reported a net loss of CHF 0.1 million in Q3 2024, compared to a net loss of CHF 0.3 million in Q3 2023, indicating a worsening financial performance year-over-year.
R&D Expense Increase: Continuing R&D expenses were CHF 0.2 million primarily related to the GABAB PAM program, which increased by CHF 0.3 million in Q3 2024 compared to Q3 2023, reflecting higher costs in research activities.
Net Loss from Associates: The company recognized CHF 0.9 million in net loss from associates, which relates to the investment in the Neurorsterix group, indicating financial strain from this partnership.
Current Liabilities Decrease: Current liabilities decreased by CHF 2 million as of September 30, 2024, compared to December 31, 2023, primarily related to CRO-related accruals and payables, suggesting potential cash flow issues.
Currency Management Vulnerabilities: The company faced foreign exchange losses on U.S. dollar cash balances, which negatively impacted the financial results, highlighting vulnerabilities in currency management.
ADXN FAQs
How does ADXN typically perform around its earnings report dates?
Is Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ADXN Earning Call Sentiment
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ADXN.O
-2.94%Positive
The earnings call summary highlights strong financial performance with a 25% increase in revenue and reduced net loss. The partnership with Indivior and a share repurchase program further boost sentiment. Despite some risks and lack of specific guidance, the overall outlook is optimistic with new product launches and improved cash position. The Q&A session did not reveal significant negative sentiment from analysts, supporting a positive stock price reaction.
